SIREN : 440251007
DELPHARM EVREUX is a French company founded 25 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in EVREUX (27000), this company of category ETI shows in 2025 a revenue of 18.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18 681 623 € | 24 191 903 € | 25 211 929 € | 25 518 972 € | 23 957 418 € | 24 772 593 € | 23 321 132 € | 22 451 312 € | 21 903 240 € | 21 703 490 € |
| Net income | -3 444 460 € | -3 496 504 € | -3 388 905 € | -1 753 362 € | -2 639 677 € | -1 792 051 € | -3 012 699 € | -2 730 956 € | -2 643 103 € | -1 774 912 € |
| EBITDA | -875 839 € | -1 163 108 € | -1 590 977 € | -854 915 € | -1 285 987 € | -359 737 € | -1 230 463 € | -1 255 569 € | -1 088 836 € | -504 844 € |
| Net margin | -18.4% | -14.5% | -13.4% | -6.9% | -11.0% | -7.2% | -12.9% | -12.2% | -12.1% | -8.2% |
In 2025, DELPHARM EVREUX achieves revenue of 18.7 M€. Activity remains stable over the period (CAGR: -1.7%). Significant drop of -23% vs 2024. After deducting consumption (5.2 M€), gross margin stands at 13.5 M€, i.e. a rate of 72%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -876 k€, representing -4.7% of revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -3.4 M€ (-18.4% of revenue), which will impact equity.
18 681 623 €
13 470 223 €
-875 839 €
-2 977 045 €
-3 444 460 €
-4.7%
The debt ratio (= Financial debt / Equity x 100) stands at -2626%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -2%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
-2626.256%
-1.9%
-7.111%
-6.456
34.3%
In 2025, the debt ratio of DELPHARM EVREUX (-2626.26) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2025, the financial autonomy of DELPHARM EVREUX (-1.9%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
In 2025, the repayment capacity of DELPHARM EVREUX (-6.46) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 135.38. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
135.381
-56.865
In 2025, the liquidity ratio of DELPHARM EVREUX (135.38) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2025, the interest coverage of DELPHARM EVREUX (-56.9x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 50 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 83 days. Excellent situation: suppliers finance 33 days of the operating cycle (retail model). Inventory turnover is 77 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 55 days of revenue, i.e. 2.9 M€ to permanently finance. Notable WCR improvement over the period (-54%), freeing up cash.
2 861 277 €
50 j
83 j
77 j
55 j
Compare DELPHARM EVREUX with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of DELPHARM EVREUX in 2025 is 18.7 M€.
DELPHARM EVREUX recorded a net loss in 2025.
The headquarters of DELPHARM EVREUX is located in EVREUX (27000), in the department Eure.
The tax return of DELPHARM EVREUX is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
DELPHARM EVREUX operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.